XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 44.54

Change

+0.51 (+1.16)%

Market Cap

N/A

Volume

0.02M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.12 (+0.08%)

USD 41.71B
FHLC Fidelity® MSCI Health Care In..

+0.15 (+0.21%)

USD 2.97B
FXH First Trust Health Care AlphaD..

+0.57 (+0.53%)

USD 1.23B
XHE SPDR® S&P Health Care Equipme..

+0.92 (+1.06%)

USD 0.22B
IDNA iShares Genomics Immunology an..

+0.42 (+1.74%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.70 (+1.89%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+0.59 (+0.63%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.36 (+1.25%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

+0.71 (+1.15%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.49 (+1.80%)

USD 0.01B

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.02% 38% F 47% F
Dividend Return 1.26% 94% A 25% F
Total Return 8.27% 48% F 41% F
Trailing 12 Months  
Capital Gain 14.06% 14% F 42% F
Dividend Return 1.79% 94% A 25% F
Total Return 15.85% 24% F 39% F
Trailing 5 Years  
Capital Gain 24.41% 29% F 57% F
Dividend Return 4.88% 67% D+ 14% F
Total Return 29.29% 33% F 50% F
Average Annual (5 Year Horizon)  
Capital Gain 0.14% N/A N/A 37% F
Dividend Return 0.84% N/A N/A 29% F
Total Return 0.69% N/A N/A 17% F
Risk Return Profile  
Volatility (Standard Deviation) 15.30% N/A N/A 63% D
Risk Adjusted Return 5.47% N/A N/A 28% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike